Aqilion focuses on treatments for inflammatory diseases, updates company pipeline
AQILION AB (publ) has decided to expand the Alnitak program by investing resources in a project focused specifically on compounds with the potential to treat inflammatory conditions of the central nervous system (CNS). In order to prioritize projects in the company's pipeline and to make best use of the company's leading-edge expertise, Aqilion will simultaneously close the Alhena oncology project and focus exclusively on drug targets with great potential in inflammatory diseases. The goal of the Alnitak program is to develop an oral medication that specifically binds to and inhibits the
